ASX澳交所医疗健康板块五月整体下跌9% 头部权重股严重拖累 细分赛道冷热不均

五月以来全球生物科技行业风险偏好回暖，但澳洲本土因为受到龙头业绩暴雷的拖累，暂时没有跟反弹节奏。当月ASX澳大利亚证券交易所医疗健康板块整体板块下跌9%，过去12个月累计跌幅31%，明显跑输大盘同期3.5%的涨幅。

2月财报季ASX医疗股表现不佳 板块整体下跌13% 哪些个股脱颖而出？

2月份澳交所基准指数ASX 200上涨4%，创下自2019年以来最佳的单月表现，然而，继2025年以25%下挫表现垫底之后，2月份医疗保健板块再次落后，逆市下跌13.31%。

Avenira Limited (ASX: AEV) Appoints John He as Executive Chairman and CEO to Accelerate Wonarah Phosphate Project Development and Strengthen Strategic Partnerships

ACB News, Sydney – 20 October 2025: Avenira Limited (ASX: AEV), an ASX-listed battery cathode and fertiliser project developer, announced the appointment of Mr. John He as Executive Chairman and Chief Executive Officer, effective from 17 October 2025. Ms. Stephanie Yuan, former Chair and CEO, will remain on the Board as a Non-Executive Director.

Future Minerals Forum 2026 to Convene Global Leaders in Riyadh, Focusing on Energy Transition and Sustainable Development

ACB News, Sydney 29 Sep 2025 — The Future Minerals Forum (FMF) 2026 will take place from 13–15 January 2026 at the King Abdulaziz International Conference Center in Riyadh, Saudi Arabia. Organized under the auspices of the Saudi Ministry of Industry and Mineral Resources, the forum is positioned as a premier global platform dedicated to shaping the future of minerals and metals amid the accelerating global energy transition.

A new platform suggests a new dimension of China's development

At a time when the global economic structure is undergoing profound adjustments and technological changes are accelerating, China is breaking through with a higher level of institutional opening.

2月份澳交所生物科技板块表现惨淡 分析师称抛盘之后呈现绝佳机遇

券商Wilsons的分析师Shane Storey博士表示，2月份财报季澳交所生物科技板块经历大范围暴跌，但其中也创造出新的买入机会。

2月份澳交所生物科技板块表现惨淡 分析师称抛盘之后呈现机遇

券商Wilsons的分析师Shane Storey博士表示，2月份财报季澳交所生物科技板块经历大范围暴跌，但其中也创造出新的买入机会。

【异动股】Medical Developments International (ASX:MVP)飙涨20%：本财年末预计实现正向现金流

Medical Developments International Ltd (ASX股票代码:MVP)股价异动，周一MVP澳交所股价飙涨19.55%，报0.795澳元，成交量144万股。今年以来该股上涨96.30%。